The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn(University of California, Los Angeles), John Crown(Cancer Trials Ireland), István Láng(National Institute of Criminology), Katalin Boér(Szent János Kórház), Igor M Bondarenko(Dnipro State Medical University), Sergey O. Kulyk, Johannes Ettl(Technical University of Munich), Ravindranath Patel(Comprehensive Blood & Cancer Center), Tamás Pintér(Petz Aladár Megyei Oktató Kórház), Marcus Schmidt(Johannes Gutenberg University Mainz), Yaroslav Shparyk(Lviv National Musical Academy named after Mykola Lysenko), Anu Thummala(Comprehensive Cancer Centers of Nevada), Nataliya L. Voytko(Kyiv City Clinical Oncology Center), Camilla Fowst(Pfizer (Italy)), Xin Huang(Pfizer (United States)), Sindy T. Kim(Pfizer (United States)), Sophia Randolph(Pfizer (United States)), Dennis J. Slamon(University of California, Los Angeles)
Cited by 1,908
Abstract
Related Papers
No related papers found
Powered by citation graph analysis